Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Case

Psychiatry Patton, CA Medical Doctor

NPI 1407808785 CMS profile 335295

3102 East Highland Ave, Patton, CA 92369

Open in the dashboard

General payments

$14,706

536 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Case of Patton, CA is reported in the CMS Open Payments database as having received $14,706 across 536 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,634 111
2024 General $773 49
2023 General $2,796 62
2022 General $1,092 71
2021 General $1,828 131
2020 General $725 48
2019 General $859 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Case
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Edward Case were reported at $6,634. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Edward Case Psychiatry median Middle half National median
2019 $859 $184 $59–$605 $163
2020 $725 $119 $36–$372 $114
2021 $1,828 $143 $43–$576 $132
2022 $1,092 $153 $50–$590 $149
2023 $2,796 $170 $56–$651 $160
2024 $773 $179 $57–$673 $164
2025 $6,634 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $6,152 149 payments
  2. Corium, Inc. $2,443 29 payments
  3. Otsuka America Pharmaceutical, Inc. $761 67 payments
  4. Teva Pharmaceuticals USA, Inc. $757 40 payments
  5. ITI, Inc. $749 38 payments
  6. Sunovion Pharmaceuticals Inc. $651 33 payments
  7. Allergan Inc. $576 42 payments
  8. Neurocrine Biosciences, Inc. $483 24 payments
  9. E.R. Squibb & Sons, L.L.C. $422 18 payments
  10. Axsome Therapeutics, Inc. $420 17 payments
  11. Other $1,292 79 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,767 526 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,180 3 payments
  3. Education $398 6 payments
  4. Consulting Fee $360 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $5,201 63 payments
  2. Azstarys $2,443 29 payments
  3. VRAYLAR Neuroscience $897 80 payments
  4. LATUDA $651 33 payments
  5. CAPLYTA $590 33 payments
  6. REXULTI Psychiatry $487 42 payments
  7. UBRELVY $478 38 payments
  8. INGREZZA $417 19 payments
  9. REXULTI Psychiatry $413 23 payments
  10. Auvelity $391 15 payments
  11. Other $3,351 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

654

Median for Psychiatry & Neurology: 100

Drug cost

$89,202

Median for Psychiatry & Neurology: $2,986

Branded share of claims

30.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 19 $28,803
Rexulti Brexpiprazole Brand 17 $25,064
Belsomra Suvorexant Brand 46 $22,013
Asenapine Maleate Generic 11 $4,448
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 57 $1,719
Buspirone Hcl Generic 57 $878
Prazosin Hcl Generic 19 $740
Olanzapine Generic 19 $697
Duloxetine Hcl Generic 31 $625
Quetiapine Fumarate Generic 35 $564

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $255
$255 — —
VRAYLAR
  • AbbVie, Inc. $158
$158 19 —
REXULTI
  • Lundbeck LLC $62
  • Otsuka America Pharmaceutical, Inc. $46
$107 17 —
Azstarys
  • Corium, Inc. $41
$41 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

536 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record